Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Qi Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6096-0690; OpenAlex author ID A5101429850, A5121408733. Sources: OpenAlex.

Their work

Papers
24 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 5 papers · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 5 papers

Papers 24

  1. Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer. Co-author DOI 10.1038/s41467-026-74315-2↗
  2. Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41467-026-77665-z↗
  3. Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. Last author DOI 10.1038/s44321-026-00506-5↗
  4. Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer: A Retrospectively Observa… Co-author DOI 10.1097/sla.0000000000006600↗
  5. MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming. Co-author DOI 10.1136/gutjnl-2025-336323↗
  6. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  7. A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer. Last author DOI 10.1038/s41388-025-03567-x↗
  8. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216607↗
  9. Cell of Origin of Pancreatic cancer: Novel Findings and Current Understanding. Co-author DOI 10.1097/mpa.0000000000002301↗
  10. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Co-author DOI 10.1038/s41591-023-02640-w↗
  11. Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cas… First author DOI 10.1097/sla.0000000000005797↗
  12. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Co-author DOI 10.1245/s10434-023-13383-w↗
  13. Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Co-author DOI 10.3389/fonc.2023.1118633↗
  14. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. First author DOI 10.1016/j.ebiom.2022.103958↗
  15. Identification of 2 Chinese Primary Pancreatic Ductal Adenocarcinoma Cancer Cell Lines and Their Phenotypes. Co-author DOI 10.1097/mpa.0000000000001932↗
  16. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  17. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  18. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1016/j.hpb.2020.01.001↗
  19. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  20. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.02.008↗
  21. Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescence to apoptosis. First author DOI 10.1016/j.ebiom.2019.08.068↗
  22. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Co-author DOI 10.1634/theoncologist.2018-0696↗
  23. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Co-author DOI 10.1016/j.canlet.2016.06.011↗
  24. Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. First author DOI 10.1038/srep13664↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 18 shared papers, 2015–2026 · strength 2.65
  2. Xueli Bai · 8 shared papers, 2016–2026 · strength 0.96
  3. Qihan Fu · 6 shared papers, 2016–2023 · strength 0.76
  4. Tingbo Liang · 3 shared papers, 2020–2026 · strength 0.54
  5. Risheng Que · 5 shared papers, 2019–2023 · strength 0.50
  6. Yunhua Liu · 2 shared papers, 2026 · strength 0.49
  7. Xiang Li · 5 shared papers, 2019–2020 · strength 0.48
  8. Jianxin Wang · 3 shared papers, 2020–2023 · strength 0.45
  9. Tao Ma · 2 shared papers, 2023–2026 · strength 0.41
  10. Tianan Jiang · 2 shared papers, 2023–2026 · strength 0.41
  11. Tao Wei · 3 shared papers, 2020–2024 · strength 0.39
  12. Jin Li · 3 shared papers, 2020–2024 · strength 0.39
  13. Min Zhang · 2 shared papers, 2023 · strength 0.30
  14. Chenlei Zheng · 1 shared paper, 2024 · strength 0.28
  15. Jiaqi Yang · 3 shared papers, 2015–2022 · strength 0.28
  16. Guoliang Qiao · 1 shared paper, 2026 · strength 0.26
  17. Ningna Weng · 1 shared paper, 2026 · strength 0.26
  18. Zhe Zhang · 1 shared paper, 2026 · strength 0.26
  19. Xiang Li · 1 shared paper, 2026 · strength 0.26
  20. Yi Zang · 1 shared paper, 2026 · strength 0.26
  21. Xinhui Su · 1 shared paper, 2026 · strength 0.26
  22. Yiwen Chen · 3 shared papers, 2016–2020 · strength 0.25
  23. Zhongkun Liu · 1 shared paper, 2026 · strength 0.25
  24. Xueli Bai · 3 shared papers, 2015–2020 · strength 0.25
  25. Yang Chen · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.